Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$53.6m

Protara Therapeutics Future Growth

Future criteria checks 0/6

Protara Therapeutics's earnings are forecast to decline at 4.7% per annum while its annual revenue is expected to grow at 77.5% per year. EPS is expected to grow by 11% per annum.

Key information

-4.7%

Earnings growth rate

11.0%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate77.5%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Nov 22
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

Aug 08
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Dec 16
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Apr 22
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

The Prognosis For Protara Therapeutics

Oct 13

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Mar 21
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Earnings and Revenue Growth Forecasts

NasdaqGM:TARA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264-69-58N/A3
12/31/2025N/A-58-48N/A3
12/31/2024N/A-45-38N/A3
9/30/2024N/A-42-35-35N/A
6/30/2024N/A-41-33-33N/A
3/31/2024N/A-42-35-35N/A
12/31/2023N/A-40-38-38N/A
9/30/2023N/A-69-34-34N/A
6/30/2023N/A-67-33-33N/A
3/31/2023N/A-64-28-28N/A
12/31/2022N/A-66-27-26N/A
9/30/2022N/A-37-28-28N/A
6/30/2022N/A-40-29-29N/A
3/31/2022N/A-45-34-34N/A
12/31/2021N/A-47-35-35N/A
9/30/2021N/A-46-35-34N/A
6/30/2021N/A-43-33-32N/A
3/31/2021N/A-37-29-28N/A
12/31/2020N/A-34-24-23N/A
9/30/2020N/A-28-18-18N/A
6/30/2020N/A-22-16-15N/A
3/31/2020N/A-16-11-11N/A
12/31/2019N/A-8-5-5N/A
9/30/2019N/A-7-5-5N/A
12/31/2018N/A-4-3-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TARA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TARA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TARA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TARA is forecast to have no revenue next year.

High Growth Revenue: TARA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TARA's Return on Equity is forecast to be high in 3 years time


Discover growth companies